In the phase III PAPILLON trial, including patients with untreated NSCLC with EGFR exon 20 insertions, the reported rates of pulmonary embolism were 7.9% with amivantamab and chemotherapy and 4.5% with chemotherapy alone, whereas the rates of deep vein thrombosis were 6.6% and 1.9%, respectively [5,19]. Here, EGFR is linked to non-small cell lung carcinoma.